SCHEMBL3532834

SCHEMBL3532834

Nc1ccc(N2CCC(N3CCCCC3)CC2)cc1N

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 16/20 0.66
L3MBTL1 Q9Y468 15/20 0.66
MBTD1 Q05BQ5 4/20 0.56
S100B P04271 2/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
PKM P14618 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TP53BP1 Q12888 4/20 0.50
L3MBTL4 Q8NA19 1/20 0.49
LRRK2 Q5S007 1/20 0.46
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13559445 0.98 L3MBTL3 (0.68) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL310165 0.86 L3MBTL1 (0.60) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL10290706 0.86 L3MBTL1 (0.60) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL30631754 0.86 L3MBTL3 (0.60) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL2892556 0.85 L3MBTL1 (0.49) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL23122819 0.84 MAPT (0.54) L3MBTL3L3MBTL1MBTD1ALDH1A1GAA
SCHEMBL29745213 0.84 LGMN (0.54) L3MBTL3L3MBTL1MBTD1MAPTALOX15
SCHEMBL15283474 0.84 L3MBTL3 (0.62) L3MBTL3L3MBTL1MBTD1S100BMEN1
SCHEMBL23122811 0.84 LGMN (0.54) L3MBTL3L3MBTL1MBTD1MAPTALOX15
SCHEMBL29745199 0.84 MAPT (0.54) L3MBTL3L3MBTL1MBTD1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK L3MBTL3 854/4885L3MBTL1 663/4885MBTD1 2871/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 L3MBTL3 4080/4885L3MBTL1 4195/4885MBTD1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.